HIGHLIGHTS
- who: Supachoke Mangmool et al. from the Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand have published the paper: New Therapeutics for Heart Failure: Focusing on cGMP Signaling, in the Journal: (JOURNAL)
- what: The phase II COSMIC-HF trial aimed to investigate the pharmacokinetic (PK) effects of omecamtiv on cardiac function and structure in HFrEF patients . The study showed no significant differences in NT-proBNP levels and LAV between vericiguat and placebo groups. The results of the study showed that, compared with the placebo, vericiguat did not lead to any improvement in the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.